Last reviewed · How we verify
EV71
At a glance
| Generic name | EV71 |
|---|---|
| Sponsor | Zhejiang Provincial Center for Disease Control and Prevention |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell). (PHASE1,PHASE2)
- Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial (PHASE1,PHASE2)
- A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years (PHASE3)
- Study on the Persistence of Immunity Following EV71 Vaccination
- Clinical Trial for Batch Consistency of EV71 Vaccine (PHASE4)
- Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell) (PHASE3)
- A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children (PHASE3)
- Active Case Finding of Clinical Hand Foot Mouth Disease in Children Aged 6 Months Old to 18 Years Old in Indonesia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EV71 CI brief — competitive landscape report
- EV71 updates RSS · CI watch RSS
- Zhejiang Provincial Center for Disease Control and Prevention portfolio CI